Focus Partners Wealth
ANIK icon

Focus Partners Wealth’s Anika Therapeutics ANIK Stock Holding History

Focus Partners Wealth’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
+10,088
New +$150K ﹤0.01% 2568

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Focus Partners Wealth's ANIK Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Anika Therapeutics (ANIK) in Q2 2026: 10,088 shares worth $148K. The stake represents ﹤0.01% of the portfolio and ranks #2568 among its holdings.

133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Focus Partners Wealth held 10,088 shares of Anika Therapeutics worth $148K as of Q2 2026.
  • Anika Therapeutics was a new Focus Partners Wealth position in Q2 2026.
  • Anika Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2568 holding.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.